Effect of Remimazolam Versus Propofol on Recovery and Cancer Outcomes After Bladder Cancer Surgery

What this Trial Is About

Bladder cancer is a common urinary system cancer, with 70-80% being nonmuscle invasive types treated primarily by transurethral resection of bladder tumor TURBT. This study evaluates the effects of remimazolam, a new benzodiazepine with rapid onset and short action, on emergency delirium and cancer recurrence after bladder cancer surgery. Researchers are interested in comparing remimazolam to propofol anesthesia and understanding its impact on postoperative delirium and long-term cancer outcomes. Participants are randomly assigned to receive either remimazolam or propofol intravenously for anesthesia induction and maintenance during bladder tumor surgery. The anesthesia dose is adjusted to maintain a specific brain activity level Bispectral Index between 40 and 60. Pain relief and muscle relaxation are provided with other medications, and inhaled sevoflurane may be given if needed. Both groups receive similar supportive drugs to manage pain and muscle relaxation. During the study, patients are closely monitored for early emergence delirium within 2 hours post-surgery and for recurrence-free survival up to 3 years. Other outcomes include postoperative delirium, nausea, awareness during surgery, hospital stay length, complications, and survival rates. Assessments include clinical evaluations in the recovery unit and follow-up visits over several years to measure cancer recurrence and quality of life.

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery